Skip to content

Telehealth-Based Chronic Disease Management for Type 2 Diabetes

Application and Evaluation of Telehealth-Based Chronic Disease Management for Type 2 Diabetes

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06719050
Acronym
T2DMTH
Enrollment
1636
Registered
2024-12-05
Start date
2024-12-18
Completion date
2027-12-31
Last updated
2024-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 DM

Brief summary

This study will be conducted from enrollment until the end of the six-month follow-up period. This study aims to assess the impact of the Internet hospital online + offline integrated chronic disease management model on patients with type 2 diabetes mellitus. It will also evaluate the economic impact of the model and identify the characteristics of the appropriate population for the model. Finally, it will develop a toolkit to help manage chronic diseases. The study will include 1,636 patients with type 2 diabetes who did not reach the standard of control target of glucose, blood pressure or LDL at the endocrine outpatient clinic and inpatient wards of the Third Hospital of Peking University. We will collect information from participants before the study starts. And the patients will be followed up for 6 months from enrollment. The study management mode included online and offline integrated management in the Internet hospital, and routine offline management mode. After completing the enrollment and assessment, we will arrange outpatient follow-up and management according to the current status, doctor's requirements, and study subjects' needs.

Interventions

None listed

Sponsors

Zeng Lin, Ph. D.
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* 18-70 years old; * Confirmed diagnosis of type 2 diabetes mellitus; * Ability to use smartphones to participate in online diagnosis and treatment; * Ability of the patient or relatives to assist the patient in self-monitoring of blood glucose; * Failure to meet control targets: glycated hemoglobin ≥7. 0%, or LDL-C ≥ 2.6 mmol/L (and ASCVD or definite atherosclerosis with stenosis ≥ 1.8 mmol/L), or blood pressure \> 130% and ≥ 1.8 mmol/kg. L), or blood pressure over 130/80 mmHg.

Exclusion criteria

* Mental illness, cognitive dysfunction; * Other diseases and complex conditions (untreated tumors, heart disease within 3 months); * Acute complications of diabetes, severe hyperglycemia, fasting glucose greater than 16.9 mmol / L, random glucose greater than 20 mmol / L. Diabetic ketoacidosis and hypoglycemic coma that are not suitable for online management of diabetes emergencies; * Patients with severe chronic complications of diabetes in critical condition (blindness, vision deterioration, new onset of ASCVD symptoms); * Those who are unsuitable for the study: infection, fracture, trauma, foot ulceration, edema, blindness, cardiovascular emergencies, coma, etc; * Those who have not signed the informed consent form.

Design outcomes

Primary

MeasureTime frame
the proportion of patients achieved all three targets (HbA1c < 7.0%, blood pressure < 130/80 mmHg and LDL-cholesterol < 2.6 mmol/L)at 6±1 month from the enrollment

Secondary

MeasureTime frame
patient satisfaction using Visual Analogue Scale (VAS)at 3±1 month from the enrollment
Hypoglycemic eventsat 3±1 month from the enrollment
Acute complicationsat 3±1 month from the enrollment
Hospitalization for any reasonat 3±1 month from the enrollment
blood glucose levelat 3±1 month from the enrollment
blood pressure assessmentat 3±1 month from the enrollment
patient adherence using 8-item Morisky Medication Adherence Scale (MMAS-8)at 3±1 month from the enrollment
diabetes self-management ability using Summary of Diabetes Self-Care Activities Questionnaire (C-SDSCA)at 6±1 month from the enrollment
diabetes self-management ability using Confidence in Diabetes Management Self-Efficacy Scale (C-DMSES)at 6±1 month from the enrollment
Direct Medical Costat 6±1 month from the enrollment
Laboratory tests for blood lipid level (Total Cholesterol, TC)at 6±1 month from the enrollment
Laboratory tests for blood lipid level (Triglycerides, TG)at 6±1 month from the enrollment
Laboratory tests for blood lipid level (High Density Lipoprotein-Cholesterol, HDL-C)at 6±1 month from the enrollment
Laboratory tests for blood lipid level (Low Density Lipoprotein-Cholesterol, LDL-C)at 3±1 month from the enrollment

Contacts

Primary ContactLin Zeng
zlwhy@163.com86+13811401686

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026